Which diabetes drug is better for heart failure? new study compares tirzepatide and semaglutide

NCT ID NCT06914141

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at over 28,000 people with type 2 diabetes and a type of heart failure called HFpEF. Researchers compared two drugs, tirzepatide and semaglutide, to see which one better reduces the risk of death or hospitalization for heart failure. The study used real-world data from insurance claims to mimic a clinical trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tirzepatide and semaglutide (drugs for diabetes and weight loss)
What this could lead to
If one drug proves clearly better, it could guide doctors to choose the most effective treatment for heart failure patients with diabetes.
What could go wrong
This is an observational study using existing data, not a controlled trial, so results may be influenced by unmeasured factors. It cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02120, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.